These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 7575649)

  • 1. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
    Greene S; Watanabe K; Braatz-Trulson J; Lou L
    Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W; Löffler M
    Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
    Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
    Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive agent leflunomide: a SWNTs-immobilized dihydroortate dehydrogenase inhibitory effect and computational study of its adsorption properties on zigzag single walled (6,0) carbon and boron nitride nanotubes as controlled drug delivery devices.
    Raissi H; Mollania F
    Eur J Pharm Sci; 2014 Jun; 56():37-54. PubMed ID: 24566615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
    Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
    J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
    Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
    Herrmann ML; Schleyerbach R; Kirschbaum BJ
    Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
    Jöckel J; Wendt B; Löffler M
    Biochem Pharmacol; 1998 Oct; 56(8):1053-60. PubMed ID: 9776318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
    Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
    Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
    J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme.
    Knecht W; Bergjohann U; Gonski S; Kirschbaum B; Löffler M
    Eur J Biochem; 1996 Aug; 240(1):292-301. PubMed ID: 8925840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
    Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
    Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
    Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR
    Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841
    [No Abstract]   [Full Text] [Related]  

  • 14. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
    Breedveld FC; Dayer JM
    Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
    Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
    J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
    Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS
    Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
    Hossain MM; Margolis DM
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
    Nair RV; Cao W; Morris RE
    Immunol Lett; 1995 Dec; 48(2):77-80. PubMed ID: 8719103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
    Xu X; Williams JW; Gong H; Finnegan A; Chong AS
    Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
    Nair RV; Cao W; Morris RE
    Immunol Lett; 1995 Sep; 47(3):171-4. PubMed ID: 8747714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.